☰

Sivan Elloul, PhD - Publications

Affiliations: 
Pathology Harvard Medical School - Beth Israel Deaconess Medical Center 
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dugast A, McArdel S, Hoover M, Hong E, Leonard SC, Bollampalli A, McLaughlin DC, Mellen J, Nissen TS, Carpenter CL, Wickham TJ, Elloul S. Abstract 3272: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profile Cancer Research. 79: 3272-3272. DOI: 10.1158/1538-7445.Am2019-3272  0.361
2017 Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB. The exportin-1 inhibitor selinexor exerts superior anti-tumor activity when combined with T cell checkpoint inhibitors. Molecular Cancer Therapeutics. PMID 28148715 DOI: 10.1158/1535-7163.Mct-16-0498  0.434
2016 Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Letters. PMID 27693556 DOI: 10.1016/J.Canlet.2016.09.016  0.424
2016 Argueta C, Chang H, Kashyap T, Elloul S, Friedlander S, Lee MS, Kauffman M, Shacham S, Senapedis W, Baloglu E. Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma Blood. 128: 3298-3298. DOI: 10.1182/Blood.V128.22.3298.3298  0.5
2016 Elloul S, Depew C, Nerle S, Chen T, Kaplan S, Dowden N, Mata-Fink J, Kahvejian A, Deans R. Engineered Erythrocytes As an Anti-Tumor Therapy through Induction of Apoptosis or Immune-Checkpoint Inhibition Blood. 128: 2166-2166. DOI: 10.1182/blood.V128.22.2166.2166  0.359
2016 Elloul S, Chang H, Klebanov B, Kashyap T, Werman M, Lee M, Landesman Y, Shacham S, Kauffman M, Friedlander SY. Abstract 4720: Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and panobinostat in a mouse model of multiple myeloma Cancer Research. 76: 4720-4720. DOI: 10.1158/1538-7445.Am2016-4720  0.495
2016 Elloul S, Chang HH, Klebanov B, Kashyap T, Werman M, Lee M, Landesman Y, Shacham S, Kauffman M, Friedlander SY. Abstract 4646: Synergistic antitumor effect of selinexor, a selective inhibitor of nuclear export (SINE) compound and trastuzumab in a mouse model of breast cancer Cancer Research. 76: 4646-4646. DOI: 10.1158/1538-7445.Am2016-4646  0.52
2016 Farren MR, Shakya R, Hennessey R, Mace T, Yang J, Elnaggar O, Young G, Landesman Y, Carlson R, Elloul S, Crochiere M, Burd C, Lesinski GB. Abstract 2319: Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma Cancer Research. 76: 2319-2319. DOI: 10.1158/1538-7445.Am2016-2319  0.438
2016 Elloul S, Chang H, Klebanov B, Kashyap T, Werman M, Lee M, Landesman Y, Shacham S, Kauffman M, Friedlander SY. Abstract 2219: Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer Cancer Research. 76: 2219-2219. DOI: 10.1158/1538-7445.Am2016-2219  0.434
2016 Elloul S, Chang H, Klebanov B, Kashyap T, Werman M, Lee M, Landesman Y, Shacham S, Kauffman M, Friedlander SY. Abstract 1299: Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumor activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models Cancer Research. 76: 1299-1299. DOI: 10.1158/1538-7445.Am2016-1299  0.492
2015 Farren MR, Shakya R, Hennessey R, Mace T, Yang J, Elnaggar O, Young G, Landesman Y, Carlson R, Elloul S, Crochiere M, Burd C, Lesinski G. Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P355  0.392
2015 Marijon H, Gery S, Elloul S, Friedlander SY, Unger T, Carlson R, Shacham S, Kauffman M, Koeffler HP. Abstract LB-255: Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows enhanced antitumor activity in combination with the PARP inhibitor, olaparib, in models of triple-negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-255  0.5
2015 Rashal T, Elloul S, Crochiere M, Kashyap T, Senapedis W, George R, Friedlander S, Ilouze M, Landesman Y, Carlson R, Peled N, Kauffman M, Shacham S, Lawrence Y. Abstract 4490: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cellsin vitroandin vivo Cancer Research. 75: 4490-4490. DOI: 10.1158/1538-7445.Am2015-4490  0.479
2015 Landesman Y, Kashyap T, Klebanov B, Elloul S, Crochiere M, Friedlander S, Senapedis W, Carlson R, Kauffman M, Shacham S. Abstract 2074: Selective inhibitor of nuclear export (SINE) compounds show synergistic anti-tumor activity in combination with dexamethasone in multiple myeloma Cancer Research. 75: 2074-2074. DOI: 10.1158/1538-7445.Am2015-2074  0.387
2015 Azmi AS, Aboukameel A, Carlson RO, Elloul S, Shacham S, Kauffman M, Frenkel R, Mohammad RM. Abstract 1756: Preclinical activity in non-Hodgkin's lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies Cancer Research. 75: 1756-1756. DOI: 10.1158/1538-7445.Am2015-1756  0.436
2014 Elloul S, Kedrin D, Knoblauch NW, Beck AH, Toker A. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Molecular Cancer Research : McR. 12: 464-76. PMID 24269953 DOI: 10.1158/1541-7786.Mcr-13-0398  0.485
2010 Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clinical & Experimental Metastasis. 27: 161-72. PMID 20213325 DOI: 10.1007/S10585-010-9315-2  0.379
2010 Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Human Pathology. 41: 794-804. PMID 20153512 DOI: 10.1016/J.Humpath.2009.09.017  0.402
2006 Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Archiv : An International Journal of Pathology. 449: 520-8. PMID 17024425 DOI: 10.1007/S00428-006-0274-6  0.382
2006 Sivertsen S, Hadar R, Elloul S, Vintman L, Bedrossian C, Reich R, Davidson B. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (Amsterdam, Netherlands). 54: 309-17. PMID 16996643 DOI: 10.1016/J.Lungcan.2006.08.010  0.321
2005 Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 103: 1631-43. PMID 15742334 DOI: 10.1002/Cncr.20946  0.345
Show low-probability matches.